Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-ttngx Total loading time: 0 Render date: 2024-05-01T17:15:31.332Z Has data issue: false hasContentIssue false

Chapter 44 - Osteoporosis and osteopenia

from Section VI - Nongynecologic conditions

Published online by Cambridge University Press:  05 May 2016

By
Ronald C. Hamdy
Edited by
Martin Olsen  and
Botros Rizk
Martin Olsen
Affiliation:
East Tennessee State University
Botros Rizk
Affiliation:
University of South Alabama
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Office Care of Women , pp. 468 - 482
Publisher: Cambridge University Press
Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation (www.nof.org); 2014.Google Scholar
NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001 Feb 14;285(6):785–95.Google Scholar
Klotzbuecher, CM, Ross, PD, Landsman, PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000;15(4):721–39.CrossRefGoogle ScholarPubMed
Harvey, N, Dennison, E, Cooper, C. Epidemiology of osteoporotic fractures. In: Rosen, CJ ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 7th edition. Hoboken, NJ: John Wiley & Sons, Inc.; 2008:198–203.Google Scholar
Chrischilles, EA, Butler, CD, Davis, CS, et al. A model of lifetime osteoporosis impact. Arch Intern Med. 1991;151(10):2026–32.CrossRefGoogle Scholar
Office of the Surgeon General (US). Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: Office of the Surgeon General (US); 2004.Google Scholar
Lauritzen, JB. Osteoporotic fractures. In: An, YH ed. Orthopaedic Issues in Osteoporosis. Boca Raton: CRC Press LLC; 2003:171–3.Google Scholar
Cooper, C, Atkinson, EJ, O’Fallon, WM, et al. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985–1989. J Bone Miner Res. 1992;7(2):221–7.CrossRefGoogle ScholarPubMed
Gehlbach, SH, Bigelow, C, Heimisdottir, M, et al. Recognition of vertebral fracture in a clinical setting. Osteoporos Int. 2000;11(7):577–82.CrossRefGoogle ScholarPubMed
Palvanen, M, Kannus, P, Parkkari, J, et al. The injury mechanisms of osteoporotic upper extremity fractures among older adults: a controlled study of 287 consecutive patients and their 108 controls. Osteoporos Int. 2000;11(10):822–31.CrossRefGoogle ScholarPubMed
Lübbeke, A, Stern, R, Grab, B, et al. Upper extremity fractures in the elderly: consequences on utilization of rehabilitation care. Aging Clin Exp Res. 2005;17(4):276–80.CrossRefGoogle ScholarPubMed
Shortt, NL, Robinson, CM. Mortality after low-energy fractures in patients aged at least 45 years old. J Orthop Trauma. 2005;19(6):396–400.CrossRefGoogle ScholarPubMed
Burge, R, Dawson-Hughes, B, Solomon, DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res. 2007 Mar;22(3):465–75.CrossRefGoogle ScholarPubMed
Nieves, JW, Bilezikian, JP, Lane, JM, et al. Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos Int. 2010;21(3):399–408.CrossRefGoogle ScholarPubMed
Leslie, WD, Sadatsafavi, M, Lix, LM, et al. Secular decreases in fracture rates 1986–2006 for Manitoba, Canada: a population-based analysis. Osteoporos Int. 2011;22(7):2137–43.CrossRefGoogle Scholar
Lippuner, K, Popp, AW, Schwab, P, et al. Fracture hospitalizations between years 2000 and 2007 in Switzerland: a trend analysis. Osteoporos Int. 2011;22(9):2487–97.CrossRefGoogle ScholarPubMed
Chevalley, T, Guilley, E, Herrmann, FR, et al. Incidence of hip fracture over a 10-year period (1991–2000): reversal of a secular trend. Bone. 2007;40(5):1284–9.CrossRefGoogle Scholar
Kannus, P, Niemi, S, Parkkari, J, et al. Nationwide decline in incidence of hip fracture. J Bone Miner Res. 2006;21(12):1836–8.CrossRefGoogle ScholarPubMed
Fisher, A, Martin, J, Srikusalanukul, W, et al. Bisphosphonate use and hip fracture epidemiology: ecologic proof from the contrary. Clin Interv Aging. 2010;5:355–62.Google ScholarPubMed
Pasco, JA, Brennan, SL, Henry, MJ, et al. Changes in hip fracture rates in southeastern Australia spanning the period 1994–2007. J Bone Miner Res. 2011;26(7):1648–54.CrossRefGoogle ScholarPubMed
Black, DM, Cummings, SR, Karpf, DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348(9041):1535–41.CrossRefGoogle ScholarPubMed
Eisman, JA, Bogoch, ER, Dell, R, et al. Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. J Bone Miner Res. 2012 Oct;27(10):2039–46.CrossRefGoogle ScholarPubMed
Hamdy, RC, Lewiecki, EM. Diagnosis In: Osteoporosis. New York: Oxford University Press; 2013: chapter 4.Google Scholar
Kanis, JA, Melton, LJ 3rd, Christiansen, C, et al. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9(8):1137–41.CrossRefGoogle ScholarPubMed
Hans, D, Downs, RW Jr, Duboeuf, F, et al. Skeletal sites for osteoporosis diagnosis: the 2005 ISCD Official Positions. J Clin Densitom. 2006;9(1):15–21.CrossRefGoogle ScholarPubMed
Hamdy, RC, Petak, SM, Lenchick, L, International Society for Clinical densitometry Position Development Panel and Scientific Advisory Committee. Which central dual x-ray absorptiometry skeletal sites and regions of interest should be used to determine the diagnosis of osteoporosis? J Clin Densitom. 2002;5(Suppl):S11–S18.CrossRefGoogle ScholarPubMed
Lewiecki, EM. Premenopausal bone health assessment. Curr Rheumatol Rep. 2005;7(1):46–52.CrossRefGoogle ScholarPubMed
Heaney, RP, Abrams, S, Dawson-Hughes, B, et al. Peak bone mass. Osteoporos Int. 2000;11(12):985–1009.CrossRefGoogle ScholarPubMed
Katzman, DK, Bachrach, LK, Carter, DR, et al. Clinical and anthropometric correlates of bone mineral acquisition in healthy adolescent girls. J Clin Endocrinol Metab. 1991;73(6):1332–9.CrossRefGoogle ScholarPubMed
Kanis, JA, Hans, D, Cooper, C, et al. Interpretation and use of FRAX in clinical practice. Osteoporos Int. 2011 Sep;22(9):2395–411.CrossRefGoogle ScholarPubMed
Lewiecki, EM, Compston, JE, Miller, PD, et al. Official Positions for FRAX® Bone Mineral Density and FRAX® simplification from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. J Clin Densitom. 2011;14(3):226–36.CrossRefGoogle ScholarPubMed
Hans, DB, Kanis, JA, Baim, S, et al. Joint official positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. Executive summary of the 2010 Position Development Conference on Interpretation and use of FRAX® in clinical practice. J Clin Densitom. 2011;14(3):171–80.Google ScholarPubMed
Schoene, D, Wu, SM, Mikolaizak, AS, et al. Discriminative ability and predictive validity of the timed up and go test in identifying older people who fall: systematic review and meta-analysis. J Am Geriatr Soc. 2013 Feb;61(2):202–8.CrossRefGoogle ScholarPubMed
Rizzoli, R. Bisphosphonates for post-menopausal osteoporosis: are they all the same? QJM. 2011;104(4):281–300.CrossRefGoogle ScholarPubMed
Nancollas, GH, Tang, R, Phipps, RJ, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006;38(5):617–27.CrossRefGoogle Scholar
Cummings, SR, Black, DM, Thompson, DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280(24):2077–82.CrossRefGoogle ScholarPubMed
Black, DM, Thompson, DE, Bauer, DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab. 2000;85(11):4118–24.CrossRefGoogle ScholarPubMed
Pols, HA, Felsenberg, D, Hanley, DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporosis Int. 1999;9(5):461–8.CrossRefGoogle Scholar
McClung, MR, Geusens, P, Miller, PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344(5):333–40.CrossRefGoogle ScholarPubMed
Watts, NB, Josse, RG, Hamdy, RC, et al. Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab. 2003;88(2):542–9.CrossRefGoogle ScholarPubMed
Harris, ST, Watts, NB, Genant, HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA. 1999;282(14):1344–52.CrossRefGoogle ScholarPubMed
Chesnut, CH III, Skag, A, Christiansen, C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19(8):1241–49.CrossRefGoogle ScholarPubMed
Black, DM, Delmas, PD, Eastell, R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809–22.CrossRefGoogle ScholarPubMed
Black, DM, Reid, IR, Boonen, S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012;27:243–54.CrossRefGoogle Scholar
Boonen, S, Black, DM, Colón-Emeric, CS, et al. Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc. 2010;58(2):292–9.CrossRefGoogle Scholar
Lyles, KW, Colón-Emeric, CS, Magaziner, JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799–1809.CrossRefGoogle ScholarPubMed
Eriksen, EF, Lyles, KW, Colón-Emeric, CS, et al. Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. J Bone Miner Res. 2009;24(7):1308–13.CrossRefGoogle ScholarPubMed
McClung, MR, Miller, PD, Brown, JP, et al. Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet. Osteoporos Int. 2012;23(1):267–76.CrossRefGoogle ScholarPubMed
Chapurlat, RD, Delmas, PD. Drug insight: bisphosphonates for postmenopausal osteoporosis. Nat Clin Pract Endocrinol Metab. 2006;2(4):211–19.CrossRefGoogle ScholarPubMed
Barrett-Connor, E, Swern, AS, Hustad, CM, et al. Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials. Osteoporos Int. 2012;23(1):233–45.CrossRefGoogle ScholarPubMed
Papapetrou, PD. Bisphosphonate-associated adverse events. Hormones (Athens). 2009;8(2):96–110.CrossRefGoogle ScholarPubMed
Procianoy, F, Procianoy, E. Orbital inflammatory disease secondary to a single-dose administration of zoledronic acid for treatment of postmenopausal osteoporosis. Osteoporos Int. 2010;21(6):1057–8.CrossRefGoogle ScholarPubMed
Abrahamsen, B. Adverse effects of bisphosphonates. Calcif Tissue Int. 2010;86(6):421–35.CrossRefGoogle ScholarPubMed
Cummings, SR, San Martin, J, McClung, MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–65.CrossRefGoogle ScholarPubMed
Boonen, S, Adachi, JD, Man, Z, et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab. 2011;96(6):1727–36.CrossRefGoogle ScholarPubMed
Brown, JP, Bone, HG, Chapurlat, R, et al. Six years of denosumab treatment in postmenopausal women with osteoporosis: results from the first three years of the FREEDOM extension. Presented at ACR; Chicago; November 2011.Google Scholar
Singer, A, Gruaer, A. Denosumab for the management of postmenopausal osteoporosis. Postgrad Med. 2010;122:176–87.CrossRefGoogle ScholarPubMed
Ettinger, B, Black, DM, Mitlak, BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282(7):637–45.CrossRefGoogle ScholarPubMed
Hamdy, RC, Daley, DN. Oral calcitonin. Int J Women’s Health. 2012:4;471–9.Google ScholarPubMed
Chesnut, CH 3rd, Silverman, S, Andriano, K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 2000;109(4):267–76.CrossRefGoogle ScholarPubMed
Ofluoglu, D, Akyuz, G, Unay, O, et al. The effect of calcitonin on beta-endorphin levels in postmenopausal osteoporotic patients with back pain. Clin Rheumatol. 2007;26(1):44–9.CrossRefGoogle ScholarPubMed
Neer, RM, Arnaud, CD, Zanchetta, JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–41.CrossRefGoogle ScholarPubMed
Leder, BZ, Neer, RM, Wyland, JJ, et al. Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis. J Clin Endocrinol Metab. 2009;94(8):2915–21.CrossRefGoogle ScholarPubMed
Andrews, EB, Gilsenan, AW, Midkiff, K, et al. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res. 2012 Dec;27(12):2429–37.CrossRefGoogle ScholarPubMed
Ross, AC, Taylor, CL, Yaktine, AL, Del Valle, HB, editors. Dietary Reference Intakes for Calcium and Vitamin D. Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium. Washington, DC: National Academies Press (US); 2011.Google Scholar
Rivlin, RS. Keeping the young-elderly healthy: is it too late to improve our health through nutrition? Am J Clin Nutr. 2007;86(5):1572S–6S.CrossRefGoogle ScholarPubMed
Munger, RG, Cerhan, JR, Chiu, BC. Prospective study of dietary protein intake and risk of hip fracture in postmenopausal women. Am J Clin Nutr. 1999;69(1):147–52.CrossRefGoogle ScholarPubMed
Body, JJ, Bergmann, P, Boonen, S, et al. Non-pharmacological management of osteoporosis: a consensus of the Belgian Bone Club. Osteoporos Int. 2011;22(11):2769–88.CrossRefGoogle ScholarPubMed
Kiel, DP, Felson, DT, Hannan, MT, et al. Caffeine and the risk of hip fracture: the Framingham Study. Am J Epidemiol. 1990;132(4):675–84.CrossRefGoogle ScholarPubMed
Tucker, KL, Morita, K, Qiao, N, et al. Colas, but not other carbonated beverages, are associated with low bone mineral density in older women: The Framingham Osteoporosis Study. Am J Clin Nutr. 2006;84(4):936–42.CrossRefGoogle Scholar
Yan, C, Avadhani, NG, Iqbal, J. The effects of smoke carcinogens on bone. Curr Osteoporos Rep. 2011;9(4):202–9.CrossRefGoogle ScholarPubMed
Maurel, DB, Boisseau, N, Benhamou, CL, Jaffre, C. Alcohol and bone: review of dose effects and mechanisms. Osteoporos Int. 2012 Jan;23(1):1–16.CrossRefGoogle ScholarPubMed
Maurel, DB, Boisseau, N, Benhamou, CL, et al. Alcohol and bone: review of dose effects and mechanisms. Osteoporos Int. 2012;23(1):1–16.CrossRefGoogle ScholarPubMed
Abukhadir, SS, Mohamed, N, Mohamed, N. Pathogenesis of alcohol-induced osteoporosis and its treatment: a review. Curr Drug Targets. 2013 Dec;14(13):1601–10.CrossRefGoogle ScholarPubMed
Nikander, R, Sievänen, H, Heinonen, A, et al. Targeted exercise against osteoporosis: A systematic review and meta-analysis for optimising bone strength throughout life. BMC Med. 2010;8:47–63.CrossRefGoogle ScholarPubMed
Howe, TE, Shea, B, Dawson, LJ, et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev. 2011 Jul;6(7):CD000333.Google Scholar
Langsetmo, L, Hitchcock, CL, Kingwell, EJ, et al. Physical activity, body mass index and bone mineral density-associations in a prospective population-based cohort of women and men: the Canadian Multicentre Osteoporosis Study (CaMos). Bone. 2012;50(1):401–8.CrossRefGoogle Scholar
Shane, E, Burr, D, Abrahamsen, B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29(1):1–23.CrossRefGoogle ScholarPubMed
Black, DM, Kelly, MP, Genant, HK, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010;362(19):1761–71.CrossRefGoogle ScholarPubMed
Khosla, S, Burr, D, Cauley, J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22(10):1479–91.CrossRefGoogle ScholarPubMed
Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws. American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65(3):369–76.Google Scholar
US Preventive Services Task Force. Screening for Osteoporosis: US Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2011;154:356–64.Google Scholar
Lim, LS, Hoeksema, LJ, Sherin, K, et al. Screening for osteoporosis in the adult US population: ACPM position statement on preventive practice. Am J Prev Med. 2009;36(4):366–75.CrossRefGoogle ScholarPubMed
Watts, NB, Bilezikian, JP, Camacho, PM, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract. 2010 Nov–Dec;16(Suppl 3):1–37.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×